
ASH 2023 Post Conference Perspectives: Highlights in Multiple Myeloma


Rafael Fonseca, MD, discusses findings from the PERSEUS trial presented in December at ASH 2023.

A medical expert navigates the treatment landscape for patients newly diagnosed with multiple myeloma.

The IsKia trial findings presented at ASH 2023 are highlighted by Dr Fonseca.

The MonumenTAL-2 study is discussed by Rafael Fonesca, MD.

A key opinion leader explores the integration of bispecifics into MM therapy regimens.

Dr Fonesca highlights key factors in multiple myeloma treatment affecting patient quality of life.

Dr Fonesca provides his final thoughts recapping data and findings presented at ASH 2023.
Advertisement
Advertisement
Trending on AJMC
1
Communication of Launch Prices by Drug Companies, 2022-2024
2
Top 5 Most-Read News Stories of 2025
3
Blinatumomab Boosts Survival in Pediatric ALL, but Faces Delivery Hurdles
4
Bispecifics in New Combos, New Uses, and Earlier Lines of Treatment in Myeloma
5




